Target intelligence / Profile preview

Probable ATP-dependent RNA helicase DDX5 (DDX5)

Target
DDX5
Molecular classification
Enzyme, RNA helicase, DEAD-box protein family, ATP-dependent RNA helicase
01

Overview

Probable ATP-dependent RNA helicase DDX5 (commonly known as DEAD-box protein 5 or RNA helicase p68) is an enzyme encoded by the DDX5 gene in humans. It is a member of the DEAD-box RNA helicase family, which is characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD). DDX5 participates in diverse aspects of RNA metabolism, including splicing, translation initiation, ribosome biogenesis, and regulation of non-coding RNAs, and is implicated in cell growth, division, and signal transduction pathways. Overexpression of DDX5 has been linked to various cancers, where it promotes proliferation, migration, invasion, and metastasis, and its inhibition suppresses tumor progression. DDX5 functions through ATP-dependent unwinding of RNA secondary structures and acts as a chaperone for RNA-protein complexes. DDX5 interacts with proteins such as AKAP8, DDX17, DHX9, estrogen receptor alpha, fibrillarin, HDAC1, p53, and CTCF, reflecting its wide-ranging roles in transcriptional and epigenetic regulation. No approved drugs selectively target DDX5 in clinical use; however, DDX5 is an emerging oncology therapeutic target, particularly for aggressive tumors showing high DDX5 expression. Systemic inhibition could impact essential cell processes due to its role in global RNA metabolism.

Other names
DEAD-box protein 5RNA helicase p68p68DEAD-box helicase 5
02

Mechanism of action

Inhibitors studied act by blocking ATPase/helicase activity, or by disrupting interactions with protein partners (preclinical/experimental)

03

Biological functions

RNA splicingTranslation initiationRibosome and spliceosome assemblymRNA processing and metabolismTranscription regulationCell proliferationCell cycle regulationRegulation of signal transduction pathways
04

Disease associations

CancerTumor progression and metastasisPotential role in other proliferative diseases (inferred from function)
05

Safety considerations

Potential issues include impact on normal cell RNA metabolism, cell proliferation, and general cellular homeostasis if inhibited systemically
06

Interacting drugs

None approved or specific; research inhibitors exist but no named clinical drugs
07

Biomarkers

High DDX5 protein expression may act as a biomarker for poor prognosis in certain cancers (e.g., esophageal squamous cell carcinoma)

Beyond the preview

Go deeper on Probable ATP-dependent RNA helicase DDX5 (DDX5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Probable ATP-dependent RNA helicase DDX5 (DDX5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call